For this reason, in the last decade, various pharmacological inhibitors of the MAPK pathway have been used, directed against mutated BRAF (first generation RAF inhibitors as vemurafenib, encorafenib, dabrafenib, sorafenib) or MEK (binimetinib, cobimetinib, trametinib) in tumor therapy [50,51,52,53]. Here, BRAF is linked to neoplasm.